研究单位：[1]Xcovery Holding Company,LLC[2]Union Hospital of Tongji Medical College of Huazhong Science and Techology University Wuhan,Hubei,China,420104[3]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology Wuhan,Hubei,China,430030[4]Hubei Cancer Hospital Wuhan,Hubei,China,430079[5]Hunan Cancer Hospital Changsha,Hunan,China,410006[6]The First Bethune Hospital of Jilin University Changchun,Jilin,China,130000
研究目的：
The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.
